Table 2 Baseline characteristics of converters versus non-converters to episodic migraine during the treatment
Characteristic | Converters (n = 62) | Non-converters (n = 29) | P value |
|---|---|---|---|
Female, n (%) | 54 (87.1) | 26 (89.7) | 0.727 |
Age, median (IQR) | 47 (38–51) | 53 (42–57) | 0.060 |
Years of migraine history, median (IQR) | 28 (20–33) | 29 (20–37) | 0.435 |
Years of CM history, median (IQR) | 8 (5–12) | 15 (4–22) | 0.099 |
MHDs, median (IQR) | 25 (20–30) | 30 (20–30) | 0.360 |
Acute medication days, median (IQR) | 20 (16–27) | 27.5 (20–30) | 0.063 |
Baseline NRS, median (IQR) | 8 (6–9) | 8 (8–8) | 0.349 |
Aura, n (%) | 18 (29.0) | 10 (34.4) | 0.600 |
Allodynia, n (%) | 24 (38.7) | 11 (37.9) | 0.943 |
Medication overuse, n (%) | 46 (74.2) | 25 (86.2) | 0.197 |
Prior preventive treatment failures, n (%) | 0.954 | ||
2 | 21 (33.9) | 10 (34.5) | |
> 2 | 41 (66.1) | 19 (65.5) | |
Botulinum toxin failure, n (%) | 26 (41.9) | 13 (44.8) | 0.795 |
Obesity, n (%) | 9 (14.5) | 4 (13.8) | 0.999 |
Sleep disturbances, n (%) | 19 (30.6) | 14 (48.3) | 0.103 |
Depressive symptoms, n (%) | 13 (21.0) | 6 (20.7) | 0.976 |